BBIO Stock Surges 19% With A 5-day Spree On Positive Phase 3 Trial Data
BridgeBio Pharma (BBIO) – a developer of medicines for genetic diseases and TTR stabilization – hit a 5-day winning streak, with cumulative gains over this period amounting to 19%. The company’s market cap has surged by about $2.4 Bil over the last 5 days and currently stands at $15 Bil.
The stock has YTD (year-to-date) return of 0.6% compared to -0.2% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Positive Phase 3 Infigratinib Trial Results
- Met Primary Endpoint With Statistical Significance
- Raymond James Raised Price Target To $89
- Impact: Shares Surged Over 14%, Analyst Price Target Increased
Opportunity or Trap?
Below is our take on valuation.
There is a near-equal mix of good and bad in BBIO stock given its overall Moderate operating performance and financial condition. But keeping in mind its Very High valuation, we think that the stock is Unattractive (For details, see Buy or Sell BBIO).
But here is the real interesting point.
You are reading about this 19% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for BBIO stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | BBIO | S&P 500 |
|---|---|---|
| 1D | 3.7% | -1.6% |
| 5D (Current Streak) | 19.3% | 0.5% |
| 1M (21D) | -3.9% | -1.9% |
| 3M (63D) | 14.2% | -0.2% |
| YTD 2026 | -0.6% | -0.2% |
| 2025 | 178.8% | 16.4% |
| 2024 | -32.0% | 23.3% |
| 2023 | 429.8% | 24.2% |
However, big gains can follow sharp reversals – but how has BBIO behaved after prior drops? See BBIO Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 74 S&P constituents with 3 days or more of consecutive gains and 77 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 35 | 40 |
| 4D | 14 | 31 |
| 5D | 14 | 2 |
| 6D | 7 | 2 |
| 7D or more | 4 | 2 |
| Total >=3 D | 74 | 77 |
Key Financials for BridgeBio Pharma (BBIO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $9.3 Mil | $221.9 Mil |
| Operating Income | $-599.4 Mil | $-577.4 Mil |
| Net Income | $-643.2 Mil | $-535.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $110.6 Mil | $120.7 Mil |
| Operating Income | $-133.5 Mil | $-136.4 Mil |
| Net Income | $-181.9 Mil | $-182.7 Mil |
While BBIO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.